[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630237":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":35,"centralContacts":45,"locations":52,"responsibleParty":68,"collaborators":35,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":74,"sex":80,"minAge":81,"maxAge":35,"enrollmentInfo":82,"targetDuration":35,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":99,"whyStopped":35,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Western University, Canada","OTHER",[8,15,20,25],{"label":9,"type":10,"description":11,"interventionNames":12},"Resistance Exercise + Semaglutide","EXPERIMENTAL","Participants assigned to this arm will receive injectable semaglutide once weekly for 16 weeks, in addition to participating in supervised moderate-intensity resistance exercise training three times per week for 32 weeks. Semaglutide will be administered during the first 16 weeks, followed by a 16-week exercise-only period.",[13,14],"Drug: semaglutide","Behavioral: Moderate-Intensity Resistance Exercise",{"label":16,"type":17,"description":18,"interventionNames":19},"Standard of Care + Resistance Exercise","ACTIVE_COMPARATOR","Participants assigned to this arm will receive standard of care treatment for Type 2 diabetes for 16 weeks and participate in supervised moderate-intensity resistance exercise training three times per week for 32 weeks. No semaglutide will be administered during the study period.",[14],{"label":21,"type":17,"description":22,"interventionNames":23},"Semaglutide + Balance and Tone Exercise","Participants assigned to this arm will receive injectable semaglutide once weekly for 16 weeks and participate in supervised balance-and-tone (BAT) exercise three times per week for 32 weeks. Semaglutide will be administered during the first 16 weeks, followed by a 16-week exercise-only period.",[13,24],"Behavioral: Balance and Tone (BAT) Exercise",{"label":26,"type":17,"description":27,"interventionNames":28},"Standard of Care + Balance and Tone Exercise","Participants assigned to this arm will receive standard of care treatment for Type 2 diabetes for 16 weeks and participate in supervised balance-and-tone (BAT) exercise three times per week for 32 weeks. No semaglutide will be administered during the study period.",[24],[30,36,41],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"DRUG","semaglutide","Injectable semaglutide administered once weekly by subcutaneous injection for 16 weeks, as prescribed and monitored by the study physician.",[9,21],null,{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":35},"BEHAVIORAL","Moderate-Intensity Resistance Exercise","Supervised moderate-intensity resistance exercise training performed three times per week for 32 weeks.",[9,16],{"type":37,"name":42,"description":43,"armGroupLabels":44,"otherNames":35},"Balance and Tone (BAT) Exercise","Supervised balance-and-tone (BAT) exercise performed three times per week for 32 weeks, serving as an active control exercise condition.",[21,26],[46],{"name":47,"role":48,"phone":49,"phoneExt":50,"email":51},"Olivia Ghosh-Swaby, PhD","CONTACT","5196612111","88284","oghoshsw@uwo.ca",[53],{"facility":54,"status":35,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"Western University","London","Ontario","N6A 3K7","Canada","CA",{"type":61,"coordinates":62},"Point",[63,64],-81.23304,42.98339,{"lat":64,"lon":63},[67],{"name":47,"role":48,"phone":49,"phoneExt":50,"email":51},{"type":69,"investigatorFullName":70,"investigatorTitle":71,"investigatorAffiliation":5,"oldNameTitle":35,"oldOrganization":35},"PRINCIPAL_INVESTIGATOR","Lindsay Nagamatsu","Principal Investigator","100630237","phase-4-exercise-and-diabetes-interventions-to-improve-brain-health-in-older-adults-with-type-2-diabetes-100630237",false,"NCT07485062","Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes","Metabolic Optimization and Training InterVentions for Aging and Type 2 Diabetes to Enhance Cognition: the MOTIVATE Study","MOTIVATE","Inclusion Criteria:\n\n1. Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.\n2. Community-dwelling\n3. Male or female\n4. Age ≥ 65 at the time of signing informed consent\n5. Glycated hemoglobin levels of ≥7% (i.e., A1c levels high enough to see intervention-related changes and increase eligibility for recruitment, but can exercise safely)\n6. Eligible for the Ontario Drug Benefit (inadequate glycemic control and on max tolerated dose of metformin or metformin contraindicated or inappropriate)\n7. Score \\>24\u002F30 on the Mini-Mental State Exam (MMSE)\n8. Score \\>6\u002F8 on the Lawton Instrumental Activities of Daily Living Scale (IADL)\n9. Have visual acuity of \\>20\u002F40 with or without corrective lenses\n10. Speak and understand English fluently\n11. Complete the Physical Activity Readiness Questionnaire (PAR-Q+) and obtain physician clearance to start a supervised exercise program\n12. Comfortable with a blood draw\n13. Not currently engaging in structured resistance exercise more than once per week\n\nExclusion Criteria:\n\n1. Have a medical condition for which semaglutide or exercise is contraindicated\n2. Use of a GLP-1 receptor agonist in the past 6 months (i.e., offers removal of Semaglutide from the system as it has a half-life of around 1 week; thus, 8-10 weeks are required for a washout.\n\n3\\) Have engaged regularly (\\>1\u002Fweek) in aerobic or RE within the past 6 months 4) Have a neurodegenerative disease (i.e., dementia) or psychiatric condition 5) Have had untreated depression in the past 6 months (6) Have experienced a recent vascular incident (i.e., stroke, myocardial infarction in the last 6 months.) (7) Have severe peripheral neuropathy, an active foot wound, or severe musculoskeletal\u002Fjoint disease (8) Active or untreated retinopathy (9) Taking psychotropic medications (excluding those for the treatment of depression)","ALL","65 Years",{"count":83,"type":84},164,"ESTIMATED","INTERVENTIONAL",[87],"PHASE4","Type 2 diabetes and low levels of physical activity are associated with an increased risk of cognitive decline in older adults. Improving blood sugar control and engaging in regular exercise may help support brain health and physical function in this population.\n\nThe MOTIVATE study is a randomized clinical trial designed to examine the effects of supervised exercise and diabetes treatment with semaglutide, alone or in combination, on cognitive function, physical health, and brain-related outcomes in older adults with Type 2 diabetes. Participants will be assigned to one of four study groups involving exercise training, control exercise, semaglutide treatment, or standard diabetes care.\n\nParticipants will complete supervised exercise sessions three times per week for 32 weeks, with some participants also receiving weekly semaglutide injections for 16 weeks. Assessments will include cognitive testing, physical and functional measures, blood-based metabolic markers, and brain imaging. This study aims to improve understanding of how exercise and diabetes treatments may support brain health in older adults with Type 2 diabetes.",[90,91],"Type 2 Diabetes","Cognitive Decline in Older Adults",[93,94,95,96,97,98,90],"Exercise Training","Semaglutide","Brain Health","Cognitive Function","Older Adults","Physical Activity","NOT_YET_RECRUITING","2026-03-16",{"date":102,"type":103},"2026-03-20","ACTUAL",{"date":105,"type":84},"2026-05-01",{"date":107,"type":84},"2029-05-01",{"name":5,"class":6},1]